Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes (original) (raw)
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
Martin Stagmo, Mozhgan Dorkhan
Cardiovascular Diabetology, 2009
View PDFchevron_right
Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
Otto Kamp
Circulation, 2009
View PDFchevron_right
Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect
Tetsuya Tagami
Diabetes Care, 2003
View PDFchevron_right
Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction
Alfonso Perez
2008
View PDFchevron_right
Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus
Yasemin Kemal
Acta Diabetologica, 2007
View PDFchevron_right
Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study
Katerina Naka
Cardiovascular Diabetology, 2010
View PDFchevron_right
Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes
Mozhgan Dorkhan
Diabetes Research and Clinical Practice, 2008
View PDFchevron_right
Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control
Thomas R Konrad
Journal of the American College of Cardiology, 2005
View PDFchevron_right
Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08)
Allan Skene
Diabetes Care, 2007
View PDFchevron_right
Effect of pioglitazone on cardiac sympathovagal modulation in patients with type 2 diabetes
giovanni murialdo
Acta Diabetologica, 2011
View PDFchevron_right
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
Mozhgan Dorkhan
Journal of Internal Medicine, 2006
View PDFchevron_right
Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes
Meng Tan
Clinical chemistry, 2004
View PDFchevron_right
Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes
Roberto Nerla
Acta Diabetologica, 2010
View PDFchevron_right
Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia
Heiko Kindler
Journal of The American College of Cardiology, 2007
View PDFchevron_right
Double-Blind, Placebo-Controlled Study Nondiabetic Patients With Combined Hyperlipidemia: A Randomized, Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in
Marco Mongillo
2010
View PDFchevron_right
Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs
Dragana Lovre
The Lancet Diabetes & Endocrinology, 2017
View PDFchevron_right
Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone
Nobuyuki Ohte
EClinicalMedicine, 2018
View PDFchevron_right
Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care
Maria Masulli
The Journal of Clinical Endocrinology & Metabolism, 2019
View PDFchevron_right
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
Antimo Aiello
The Lancet Diabetes & Endocrinology
View PDFchevron_right
The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
farzad najafipour
Therapeutic Advances in Endocrinology and Metabolism, 2015
View PDFchevron_right
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
Toshikazu Yamanouchi
Vascular Health and Risk Management, 2010
View PDFchevron_right
Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study
Meng Tan
Clinical Therapeutics, 2005
View PDFchevron_right
Comparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease
Thomas Giles, Uri Elkayam
Congestive Heart Failure, 2009
View PDFchevron_right
Effects of Pioglitazone on Endothelial Function, Insulin Sensitivity, and Glucose Control in Subjects With Coronary Artery Disease and New-Onset Type 2 Diabetes
Robert Zweiker
Diabetes Care, 2006
View PDFchevron_right
Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus
Rebecca Sleeper, Krystal Edwards
Pharmacotherapy, 2006
View PDFchevron_right
The effect of Pioglitazone, a PPAR-γ agonist, on cardiovascular risk factors in Type 2 Diabetics a, a * b c a
Prerna Goyal
View PDFchevron_right
Rosiglitazone, but Not Pioglitazone, Improves Myocardial Systolic Function in Type 2 Diabetic Patients: A Tissue Doppler Study
Kartal KOŞUYOLU
Echocardiography, 2010
View PDFchevron_right
Efficacy and Safety of PioglitazoneVersusMetformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial
Guntram Schernthaner
The Journal of Clinical Endocrinology & Metabolism, 2004
View PDFchevron_right
Spotlight on Pioglitazone in Type 2 Diabetes Mellitus1
Dean Robinson, John Waugh
Treatments in Endocrinology, 2006
View PDFchevron_right
Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study
Jaime Davidson
Diabetes, Obesity and Metabolism, 2006
View PDFchevron_right